Land: Canada
Sprog: engelsk
Kilde: Health Canada
DIMETHYL FUMARATE
SANDOZ CANADA INCORPORATED
L04AX07
DIMETHYL FUMARATE
120MG
CAPSULE (DELAYED RELEASE)
DIMETHYL FUMARATE 120MG
ORAL
15G/50G
Prescription
MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS
Active ingredient group (AIG) number: 0154210001; AHFS:
APPROVED
2021-10-04
_Sandoz Dimethyl Fumarate Delayed-Release Capsules _ _ _ _Page 1 of 46 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr SANDOZ DIMETHYL FUMARATE DELAYED-RELEASE CAPSULES Dimethyl Fumarate Delayed-Release Capsules delayed-release capsules, 120 mg and 240 mg, oral Antineoplastic and Immunomodulating Agents Sandoz Canada Inc. 110, Rue de Lauzon Boucherville, QC, J4B 1E6 Canada Submission Control No: 280774 Date of Initial Authorization: OCT 04, 2021 Date of Revision: DEC 06, 2023 _Sandoz Dimethyl Fumarate Delayed-Release Capsules _ _ _ _Page 2 of 46 _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS 12/2023 8 ADVERSE REACTIONS, 8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data 12/2023 10 CLINICAL PHARMACOLOGY, 10.2 Pharmacodynamics 12/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS ................................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics .................................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................... 4 4 DOSAGE AND ADMINISTRATION .................................................................................... 5 4.1 Dosing Considerations .............................................................................................. 5 4.2 Læs hele dokumentet